Regor

Boston, United States Founded: 2018 • Age: 8 yrs Acquired By Roche
Provider of therapeutics related to oncology, autoimmune and metabolic disease
Request Access

About Regor

Regor is a company based in Boston (United States) founded in 2018 was acquired by Roche in September 2024.. Regor has raised $90 million across 2 funding rounds from investors including Roche, Qilu Pharmaceutical Group and Lilly Asia Ventures. Regor offers products and services including GDC-4198, RGT-075, RGT-419B, and RGT-587. Regor operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.

  • Headquarter Boston, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Regor Therapeutics Group
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $90 M (USD)

    in 2 rounds

  • Latest Funding Round
    $90 M (USD), Series B

    Feb 18, 2021

  • Investors
    Roche

    & 6 more

  • Employee Count
    Employee Count
  • Acquired by
    Roche

    (Sep 30, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Regor

Regor offers a comprehensive portfolio of products and services, including GDC-4198, RGT-075, RGT-419B, and RGT-587. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Next-generation inhibitor for breast cancer treatment in clinical trials

Oral small molecule for obesity and type 2 diabetes management

CDK inhibitor for advanced breast cancer patients

Next-gen treatment for breast cancer in phase trials

People of Regor
Headcount 50-200
Employee Profiles 17
Board Members and Advisors 2
Employee Profiles
People
Xiayang Qiu
Founder CEO
People
Min Zhong
Chief Operating Officer
People
Xiaotian Zhu
President of US Operations
People
Xi Chen
Chief Business Operation

Unlock access to complete

Board Members and Advisors
people
Janet Hammond
Scientific Advisor
people
Rikard Holmdahl
Scientific Advisor

Unlock access to complete

Funding Insights of Regor

Regor has successfully raised a total of $90M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $90 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $90.0M
  • First Round
  • Investors Count 6
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2021 Amount Series B - Regor Valuation Lilly Asia Ventures
Jun, 2018 Amount Seed - Regor Valuation Qilu Pharmaceutical Group
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Regor

Regor has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, Qilu Pharmaceutical Group and Lilly Asia Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Mid-market companies are targeted for investment by Loayal Valley Capital.
Founded Year Domain Location
TF Capital is engaged in biotech investment and strategic support.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Regor

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Regor

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Regor Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Regor

Regor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Cancer therapies are developed using selective pathway inhibitors.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Regor

Frequently Asked Questions about Regor

When was Regor founded?

Regor was founded in 2018.

Where is Regor located?

Regor is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Is Regor a funded company?

Regor is a funded company, having raised a total of $90M across 2 funding rounds to date.

What does Regor do?

Regor was founded in 2018 in Boston, United States, within the biotechnology sector. Therapeutics targeting oncology, autoimmune, and metabolic diseases are developed. A multi-disciplinary computational platform is employed, integrating structural biology, biopharmaceutics, PKPD modeling, and bioinformatics. Drug discovery processes are supported from target identification and lead optimization through to clinical proof of concept, with operations based in the United States.

Who are the top competitors of Regor?

Regor's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

What products or services does Regor offer?

Regor offers GDC-4198, RGT-075, RGT-419B, and RGT-587.

Who are Regor's investors?

Regor has 7 investors. Key investors include Roche, Qilu Pharmaceutical Group, Lilly Asia Ventures, Loayal Valley Capital, and LanTing Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available